Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs

Damen, Pim J J; Verhoeff, Joost J C

doi:https://doi.org/10.21037/tcr-22-2841

Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs

DSpace/Manakin Repository

Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma-a prospective multicenter observational study pointing out new unmet needs

Damen, Pim J J; Verhoeff, Joost J C

(2023) Translational Cancer Research, volume 12, issue 3, pp. 688 - 691

(Editorial)

Download/Full Text

Open Access version via Utrecht University Repository

Publisher version

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Checkpoint inhibitors, Response Evaluation Criteria in Solid Tumors (RECIST), abscopal response, oligoprogression, radiotherapy, Editorial, Comment

DOI: https://doi.org/10.21037/tcr-22-2841

ISSN: 2218-676X

Publisher: AME Publishing Company

(Peer reviewed)